{"nctId":"NCT00194987","briefTitle":"A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia","startDateStruct":{"date":"2001-04"},"conditions":["Alloimmune Thrombocytopenia","Fetal Alloimmune Thrombocytopenia"],"count":102,"armGroups":[{"label":"IVIG x 2","type":"EXPERIMENTAL","interventionNames":["Drug: IVIG (Intravenous Immunoglobulin)"]},{"label":"IVIG x 1 + prednisone","type":"EXPERIMENTAL","interventionNames":["Drug: IVIG (Intravenous Immunoglobulin)","Drug: prednisone"]}],"interventions":[{"name":"IVIG (Intravenous Immunoglobulin)","otherNames":[]},{"name":"prednisone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPregnant women are eligible for inclusion into the Very High Risk Group if they:\n\n* are PLA-1 (platelet antigen A1) negative and have known platelet incompatibility with their fetus\n* have had a previous child who suffered an antenatal hemorrhage prior to 28 weeks gestation (as best as could be estimated)\n* are less than 19 weeks gestation\n\nPregnant women are eligible for inclusion into the High Risk Group if they:\n\n* are PLA-1 negative and have known platelet incompatibility with the fetus\n* have had a previous child who suffered an antenatal hemorrhage after 28 weeks gestation (as best as could be estimated)\n* are between 12-30 weeks gestation\n\nPregnant women are eligible for inclusion into the Standard Risk Group if they:\n\n* are PLA-1 negative and have known platelet incompatibility with the fetus\n* have not had a previous child who suffered an antenatal hemorrhage\n* are between 20-30 weeks gestation\n\nExclusion Criteria:\n\nWomen are not eligible for inclusion into the Very High Risk Group if they:\n\n* have had a previous child who suffered an antenatal hemorrhage after 28 weeks gestation\n* are greater than 19 weeks gestation\n\nWomen are not eligible for inclusion into the High Risk Group if they:\n\n* have had a previous child who suffered an antenatal hemorrhage prior to 28 weeks gestation\n* are greater than 30 weeks gestation\n\nWomen are not eligible for inclusion into the Standard Risk Group if they:\n\n* have had a previous child who suffered an antenatal hemorrhage\n* are greater than 30 weeks gestation","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Newborns With a Birth Platelet Count > 50,000/uL","description":"this uses the birth platelet count of the fetuses from the study when they are born","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Intracranial Hemorrhage: Number Occurring in Fetuses and Newborns of Mothers in Study","description":"number of ICH assessed by fetal and neonatal ultrasound with MRI back up most commonly in utero so range from 20-40 weeks fo gestation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Fetal Platelet Counts > 50,000/uL","description":"Number of Fetal Platelet Counts \\> 50,000/uL Among Those Who Underwent Fetal Blood Sampling and Had a Fetal Platelet Count Determined","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":51},"commonTop":["headache","hypertension","IVIG dose error","diabetes mellitus","jaw tightness"]}}}